Abstract-Ambulatory blood pressure (BP) monitoring (ABPM) is the best method of detecting abnormal BP in patients with chronic kidney disease (CKD), whose hypertension may be missed with casual BP measurements. We report ABPM findings in 332 children 1 year after entry in the Chronic Kidney Disease in Children cohort study. All of the subjects underwent casual and ambulatory BP measurement. BP was categorized based on casual and ABPM results into normal (42%), white-coat (4%), masked (35%), and ambulatory (14%) hypertension. Only half of the subjects had a normal ABPM. BP load was elevated (Ͼ25%) in 52% (nϭ172), whereas mean BP was elevated in 32% (nϭ105). In multivariate analysis, those using an angiotensin-converting enzyme inhibitor were 89% more likely to have a normal ABPM than those who did not report using an angiotensin-converting enzyme inhibitor (odds ratio, 1,2 HTN is also common in children with CKD. We have shown previously that Ͼ25% of children with CKD had elevated casual blood pressure (BP), and nearly one third of these were not receiving antihypertensive medications, indicating that HTN in pediatric CKD may be frequently undertreated or even untreated entirely. Ambulatory BP monitoring (ABPM) is a more accurate technique than casual BP measurement to stratify cardiovascular risk, especially in patients with CKD, [4] [5] [6] and is also more predictive of disease progression.
U ncontrolled hypertension (HTN) is a known risk factor for increased cardiovascular morbidity and for progression of chronic kidney disease (CKD) in adults.
1,2 HTN is also common in children with CKD. We have shown previously that Ͼ25% of children with CKD had elevated casual blood pressure (BP), and nearly one third of these were not receiving antihypertensive medications, indicating that HTN in pediatric CKD may be frequently undertreated or even untreated entirely. 3 Ambulatory BP monitoring (ABPM) is a more accurate technique than casual BP measurement to stratify cardiovascular risk, especially in patients with CKD, [4] [5] [6] and is also more predictive of disease progression. [7] [8] [9] [10] [11] [12] [13] [14] Few studies, however, have characterized the prevalence of ambulatory HTN in CKD or quantified the association between the degree of ambulatory HTN and other factors related to the progression of kidney disease in children.
In this report, we summarize the initial ABPM data collected from participants in the Chronic Kidney Disease in Children (CKiD) Study, a multicenter observational cohort study being conducted in the United States and Canada. Our aims in this report were as follows: (1) to present our experience with coordinating ABPM across a North American multicenter study; (2) to describe the distribution of ambulatory BP, HTN, and antihypertensive medication use in this large cohort of children with CKD; and (3) to investigate the association between markers of kidney disease progression after Ͼ1 year and the presence of abnormal ambulatory BP.
Study protocol was reviewed and approved by the institutional review boards of each participating center.
Children eligible for enrollment were between 1 and 16 years of age, with an estimated Schwartz formula 16 glomerular filtration rate (GFR) of 30 to 90 mL/min per 1.73 m 2 and signed written informed consent by a parent or guardian with signed assent according to local requirements. Exclusion criteria included solid organ, bone marrow, or stem cell transplant; dialysis within the 3 months before enrollment; cancer or HIV treatment within the past year; pregnancy within the past year; inability to complete protocol procedures; enrollment in a randomized clinical trial in which treatment is masked; or an intent to move away from the participating center in the near future.
Casual Blood Pressure
All of the casual BPs were measured by auscultation using an aneroid sphygmomanometer (Mabis MedicKit 5, Mabis Healthcare, Waukegan, IL). Aneroid calibration and recertification in auscultatory BP measurement technique occurred annually for all of the equipment and personnel. By protocol, casual BP was measured at each CKiD visit (annual), and standardized methods for obtaining casual BP have been described previously. 3 Study personnel measured auscultatory BP 3 times at each study visit, and the mean was used as the participant's casual BP for the present analysis.
Each participant's casual BP was classified according to the National High Blood Pressure Education Program Fourth Report on the diagnosis, evaluation, and treatment of high BP in children and adolescents 17 : normotensive (Ͻ90th percentile and Ͻ120/80 mmHg), prehypertensive (Ն90th and Ͻ95th percentiles or Ͻ90th percentile and Ͼ120/80 mm Hg), and hypertensive (Ն95th percentile). In this analysis, participants' casual BP obtained within 30 days of ABPM placement were used to classify their ambulatory BP category (see below).
Ambulatory BP Monitoring
SpaceLabs 90217 monitors (SpaceLabs Healthcare, Issaquah, WA) were used for all ABPM, which occurred 1 year after study entry, and repeated every 2 years thereafter. The data described in this report were obtained 1 year after study enrollment. Monitors were sent from and analyzed at a central site at the University of Texas Health Science Center at Houston (ABPM center). Arm circumference was measured at each local site with appropriate cuffs selected according to the fourth report recommendations. 17 All of the participating clinical sites received annual training in monitor placement from the ABPM center.
Monitors were set to measure BP every 20 minutes during the day and night at a bleed step of 8 mm Hg, and participants were instructed to wear the monitor for a continuous 24-hour period. Most monitorings occurred at or near the time of the CKiD Study visit. Each participant's family was given a diary to complete, noting times of wake, sleep, and any medication administration while wearing the monitor. After completion, the monitor and diary were returned to the ABPM center for data processing and summarizing. For ABPM studies that did not fulfill prespecified quality parameters (see below), a repeat attempt was made. Summarized ABPM data were sent to the CKiD data coordinating center at the Johns Hopkins Bloomberg School of Public Health for centralized data management and analysis.
Definitions
Summary of ABPM data was performed at the ABPM Coordinating site (principal investigator, J.S.) using a standardized protocol. Quality of the ABPM studies was defined by the length of time that the monitor was actually worn and the number of successful BP recordings. Monitors worn for Ն21 hours with Ն18 hours with Ն1 valid BP measured per hour were acceptable for analysis. As additional criteria to ensure adequate representation of both wake and sleep periods, each ABPM had to have Ն1 successful BP recording in Ն75% of wake hours and Ն75% in sleep hours.
The ambulatory BP parameters of interest included mean systolic and mean diastolic BPs for parental-reported wake, sleep, and 24-hour periods. From these, systolic and diastolic BP dip statuses were determined by calculating the percentage of nocturnal drop in mean BP from waking mean values. In addition, wake and sleep BP loads were calculated as the percentage of readings Ն95th percentile, based on the published normative pediatric ABPM data from Soergel et al. 18 This normative data set has been used as the reference for ambulatory BPs. For 24-hour load calculation, a weighted sum of wake and sleep loads was used. Similarly, ambulatory BP index was calculated as the mean ambulatory BP, by wake or sleep state, divided by the corresponding 95th percentile. Thus, an index of 1 indicates an ambulatory BP equal to the threshold value for a clinical diagnosis of HTN, and an index of 1.1 is 10% above that threshold. 19 Because the 95th percentile is age, sex and height specific, this measure allows for comparison of BP across a wide range of normal pediatric values.
We also classified studies based on the recently issued American Heart Association (AHA) guidelines for pediatric ABPM. 20 Using both auscultatory clinical and 24-hour readings, ambulatory BP status was categorized using the following definitions: (1) normal BP was defined as casual BP Ͻ95th percentile, wake and sleep mean ABP Ͻ95th percentile, and wake and sleep load Ͻ25%; (2) ambulatory HTN was defined as casual BP Ն95th percentile and either wake or sleep mean ABP Ն95th percentile or either wake or sleep load Ն25%; (3) white-coat HTN was defined as casual BP Ն95th percentile, wake and sleep mean ABP Ͻ95th percentile, and wake and sleep load Ͻ25%; and (4) masked HTN was defined as casual BP Ͻ95th percentile and either wake or sleep mean ABP Ն95th percentile or either wake or sleep load Ն25%.
Given the increased risk of cardiovascular disease in patients with CKD, 21, 22 ABPM was considered abnormal when either the ambulatory mean or load was elevated. Thus, subjects with AHA classified pre-HTN (high casual BP, normal mean ambulatory BP, and high ambulatory BP load) were considered hypertensive (ie, abnormal ABPM) in this analysis. In addition, those with unclassified AHA BP parameters (normal casual, normal mean ambulatory BP, and high load) were also considered masked hypertensive in this analysis. As noted above, we chose the 1997 normative ABP data from Soergel et al 18 because this data set included shorter children and is, thus, more applicable to the CKiD population, which exhibits substantial deficits in height. 23 
Other Variables
Demographic and medical history information included age, sex, self-reported race/ethnicity, underlying CKD diagnosis, duration of CKD, a history of HTN, use of antihypertensive medications during the past 30 days, history of low birth weight (Ͻ2500 g) or premature birth (Ͻ36 weeks' gestation), and family history of HTN. GFR was measured at visit 1 and visit 2 by plasma disappearance of iohexol. 24 Laboratory analyses were performed in the CKiD central laboratory (University of Rochester, Rochester, NY).
Statistical Analysis
Descriptive statistics are presented as medians and interquartile ranges for continuous variables and percentages for categorical variables. ABPM-classified BP groups were defined as normotensive, white-coat hypertensive, masked hypertensive, confirmed hypertensive.
Because there was a high prevalence of antihypertensive medication use in this population, we were also interested in the association between the use of any antihypertensive medications, as well as a specific class of angiotensin-converting enzyme (ACE) inhibitors, and an abnormal ABPM study. We investigated this association between abnormal ABPM and antihypertensive medication use at the time of ABPM monitoring using logistic regression. In 2 models, the outcome was the presence of a normal versus abnormal ABPM, and the 2 exposures of interest were any antihypertensive use and ACE inhibitor use. The models adjusted for age, sex, CKD diagnosis type (glomerular cause versus nonglomerular cause), iohexol GFR, and urine protein:creatinine ratio (uPrCr).
In addition, we investigated the association between markers of CKD progression and the presence of an abnormal ABPM (as the dependent variable) using available longitudinal data (visits 1 and 2). CKD disease progression was characterized by 2 renal markers, GFR and uPrCr (putative exposures), which were measured at visit 1 (at study entry 1 year before the ABPM protocol) and at visit 2 (at the same time as the ABPM study). Using a logistic regression model, the outcome was the presence of abnormal ABPM, and the independent variables of interest were: 1) the annualized ratio of visit 2 level to visit 1 level in each renal marker, and 2) the geometric mean of the 2 levels. Specific confounders were identified a priori as important to control for age, sex, and CKD diagnosis. The interpretation of the coefficient is expressed as the odds ratio associated with a k-fold difference in the ratio (ie, comparing a subject whose ratio of current to previous levels Ͼ1 year is k-fold the ratio of an otherwise similar individual used as a reference). For each variable, k was determined by the SD of the annual percent change: 0.80-fold difference in the ratio of current GFR to previous GFR (ie, a 20% lower decline Ͼ1 year) and a 2.25-fold increase in uPrCr.
Statistical significance was assessed at the 0.05 level. All of the analyses were performed using SAS 9.1 statistical software (SAS Institute, Cary, NC).
Results
The first CKiD ABPM was performed on January 25, 2006 . At the time of the current analysis, there were 515 completed visit 2 records. Thirty-nine subjects never had an ABPM ordered. Of 626 shipments of ABP monitors from the coordinating center, 97% were delivered in time for subject use. A total of 402 ABPM studies were completed in 476 total subjects (84%). The most common factor leading to an unsuccessful ABPM attempt was postponement of study visit. Monitor malfunction (nϭ3) or nonreturn (nϭ5) were not major difficulties considering the geographic scope of the study. An ABPM suitable for analysis was successfully completed on the initial attempt in 276 subjects. The remaining participants who attempted an ABPM study were unable to meet the quality criteria described above or did not have a repeat measurement. A total of 126 participants had the baseline ABPM procedure repeated following their unsuccessful attempt, with about half returning quality data on the ABPM indicates ambulatory blood pressure monitoring; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; HTN, hypertension; CKD, chronic kidney disease; GFR, glomerular filtration rate; BMI, body mass index; IQR, interquartile range. For successful ABPMs, the youngest age was 2 y and the oldest was 18 y.
*P values are based on Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical variables comparing attainable to unattainable ABPM studies.
†Iohexol GFR and urine protein:creatinine were measured at visit 2, at the time of the ABPM data collection.
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second attempt (56 of 126). Despite repeat attempts, 68 participants had Ͻ21 hours of successful monitoring or missed Ͼ3 hours and, thus, were excluded. The other 2 excluded subjects had either poor wake success rate (ie, Ͻ75% of wake hours with a valid BP reading; nϭ1) or poor sleep success rate (nϭ1). Overall, there were 332 highquality ABPM studies in the present analysis. The median age of participants undergoing ABPM was 12 years (interquartile range, 9 -16 years), with a sex and ethnic mix similar to the larger CKiD cohort. Among these participants, 19% (nϭ63) had a glomerular cause of CKD. Nearly half the subjects (nϭ152) had a previous diagnosis of HTN, and 69% (nϭ224) were treated with antihypertensive medication at the time of the ABPM. Of those treated, 77% (nϭ173) were using an ACE inhibitor, and 14% (nϭ31) were using an angiotensin receptor blocker medication (Table 1) .
We compared subjects who successfully completed a study with those who were unable to do so and those who never had an ABPM study at all to understand potential barriers to collecting valid ABPM data (Table 1) . Successful subjects (nϭ332) tended to be older, of white race, heavier, and to not born prematurely compared with those who did not complete a successful study (nϭ70). There were no significant differences in sex, body mass index, GFR, hypertensive history, or antihypertensive use between these 2 groups. Those who did not complete an ABPM study tended to be similar to those who had an ABPM study that was not successful.
Descriptive Results of Ambulatory BP
Among those with a quality ABPM study, 151 subjects had a completely normal ABPM (46%). Overall, 30% were defined as hypertensive based on mean ambulatory BPs alone (either wake or sleep; Table 2 ). A higher proportion of subjects had elevated BP loads Ͼ25% during the sleep state for both systolic (33%) and diastolic (39%) measurements than during the wake state for systolic (28%) and diastolic (22%) measurements. We also investigated ambulatory HTN by wake or sleep state, where HTN was defined as a systolic or diastolic mean Ͼ95th Soergel limit or systolic or diastolic load Ͼ25%. Using this definition, sleep HTN (65%) was more prevalent than wake HTN (33%).
BP classification using combined casual and ambulatory values are summarized in Table 3 . Both casual and ambulatory measurements were normal in 138 (42%) subjects. White-coat HTN was diagnosed in only 13 subjects (4%), whereas 116 (35%) were classified as having masked HTN by ABPM criteria. There were 48 subjects (14%) with confirmed HTN, of whom 21 had "severe" ambulatory HTN (loads Ͼ50%). Although similar in sex across all of the groups, those with white-coat HTN were younger than the overall group. Ambulatory HTN was more common in blacks and slightly more common among those with glomerular disease as a primary cause of CKD. As expected from the definitions, those with masked HTN had lower casual BP than those with either white-coat HTN or ambulatory HTN. Similarly, systolic loads were much higher in subjects with masked (26%) and ambulatory HTN (47%) than those with white-coat HTN (7%). In general, those with masked HTN had more abnormal BP loads than abnormal mean BP. In addition, elevated sleep BPs were more common than elevated wake pressures.
Almost 13% of the cohort (nϭ38) had a circadian BP pattern that is not included in the 2008 AHA guidelines. These subjects had normal casual and 24-hour mean BP readings but BP loads Ͼ25%. Given that a substantial portion of ABPM readings were abnormal, and this population was already defined as a high-risk group (ie, a clinical diagnosis of CKD), we classified these subjects as having an abnormal ABPM study. 25 Thus, they were included as having masked HTN (Table 3) .
Use of Antihypertensive and ACE Inhibitor Medications
A majority of this study sample reported any antihypertensive therapy use (68%; Table 1) , and approximately half (52%) of the study sample were being treated with ACE inhibitors. There were similar proportions of subjects treated with any antihypertensive medications (ACE inhibitors, angiotensin receptor blockers, diuretics, and/or calcium channel blockers) among those with a normal ABPM (68%) and an abnormal ABPM (71%). In a logistic regression model with adjustment for age, sex, CKD diagnosis, GFR level, and uPrCr, those on any antihypertensive medications had a 13% higher odds of a normal ABPM compared with those not on any antihypertensive medications (odds ratio [OR], 1.13 [95% CI, 0.69 -1.95]), but this association was not significant. When we investigated the association with ACE inhibitor use compared with no ACE inhibitor use among all of the subjects (regardless of other antihypertensive medications), there was a stronger and significant association with this specific class of antihypertensives and the odds of having a normal ABPM: those using an ACE inhibitor were 89% more likely to have a normal ABPM than those who did not report using an ACE inhibitor (OR, 1.89 [95% CI, 1.17-3.04]). Table 4 describes the effect of annual change and average levels of GFR and uPrCr on the odds of having an abnormal ABPM. The average level of GFR between visits 1 and 2 was (1) 21% (24) 27% (13) Other 9% (13) 8% (1) 11% (13) 8% (4) Hispanic ethnicity 17% (23) 8% (1) 13% (15) 21% (10) Height percentile 27 [9- Note that 17 children were not included because missing clinic blood pressure measurements. DBP indicates diastolic blood pressure; SBP, systolic blood pressure; ABPM, ambulatory blood pressure monitoring; uP/C, urine protein/creatinine; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme; HTN, hypertension; CKD, chronic kidney disease; GFR, glomerular filtration rate; BMI, body mass index; WCH, white-coat hypertension; Hx, history.
Association of CKD Progression and Abnormal ABPM
42.5 mL/min per 1.73 m 2 , and the average level of uPrCr was 0.43. The average annual decline in GFR was 0.96 (or a decrease of Ϸ4% per year), whereas uPrCr increased by Ϸ8% per year. The SD of this annual change was 0.80 for GFR and 2.25 for uPrCr. For the 1-year longitudinal change in GFR, a 20% lower difference in the ratio of current level (visit 2) to previous level at visit 1 (ie, a 0.80-fold difference in decline, which corresponds to 1 SD of ratios of the sample) was associated with a 26% higher odds of having an abnormal ABPM independent of the average level of uPrCr and change in uPrCR and adjusting for average level of GFR at the 2 visits, age, sex, and CKD diagnosis (OR, 1.26 [95% CI, 0.97-1.64]; Pϭ0.081). This effect was borderline significant and showed that a faster decline was associated with an increased odds of having an abnormal ABPM. The effect of average GFR level was not associated with abnormal ABPM (Pϭ0.435).
A larger effect was observed for changes in uPrCr. Specifically, a 1-SD increase in uPrCr change for this population (eg, 2.25-fold increase) was associated with a 39% higher odds of having an abnormal ABPM (OR, 1.39 [95% CI, 1.06 -1.82]; Pϭ0.019) when controlling for confounders, including the average uPrCr level of the 2 visits (Table 4) . Similar to GFR, the average level of uPrCr was not related to increased odds of having an ABPM (Pϭ0.246). The interactions of the average level with average change were not significant for GFR (Pϭ0.126) and uPrCr (Pϭ0.944) and were, therefore, not included in this final model.
Discussion
ABPM is a powerful tool for the investigation of cardiovascular risk and has been endorsed for use in children in selected clinical settings. 17, 20 A major limitation to more widespread use of ABPM in children is lack of expertise in the technique: it can be challenging to ensure successful data collection in this young population. Accordingly, few multicenter studies have included ABPM. In this report, we demonstrated that ABPM can be successfully implemented in a large multicenter pediatric study if standardized procedures and central oversight are provided. We further showed the high prevalence of abnormally elevated ambulatory BP in this cohort, which was importantly detected during sleep, leading to a large proportion classified as having masked HTN. Perhaps most significantly, we also demonstrated a positive association between the presence of an abnormal ABPM and larger annual increases in uPrCr, which is an important marker for CKD progression.
Given that a diagnosis of CKD was an inclusion criterion in this cohort, our definition of ambulatory HTN is more conservative than most published reports. Although the recent AHA guidelines 20 contain classifications of abnormal ABPM studies that are not considered hypertensive (ambulatory pre-HTN), any abnormality in either wake or sleep systolic BP or diastolic BP means (ie, mean BP Ͼ95th percentile) or load (ie, load Ͼ25%) was considered diagnostic of HTN in this analysis. Compared with otherwise healthy patients with elevated BP, the high prevalence of cardiovascular complications in individuals with CKD supports this more inclusive definition. This inclusive definition of HTN also helps solve a problematic dilemma faced by clinicians: a significant number of subjects (13%) in the current analysis were found to have an ambulatory BP pattern that is not described by the guidelines. Namely, the current AHA guidelines do not address classification of ABPM studies with elevated loads but normal mean BP. In the population described in this report, many of these subjects have been diagnosed previously as hypertensive, and even more are on antihypertensive mediations, thus supporting our inclusion of them in the hypertensive group.
One potential weakness of the current analysis is the heterogeneity of subjects classified as having masked HTN. We chose to categorize subjects as having masked HTN based on inadequately controlled BP rather than excluding those with self-reported antihypertensive medication use. Although this classification may not be directly applicable to the general population, the universal diagnosis of CKD in this sample is an essential consideration. Indeed, any patient with CKD and abnormal circadian variation in BP is likely at increased risk of adverse health outcomes, regardless of previous diagnosis or current treatment. In addition, another asset to using ABPM is in determining the effectiveness of therapy, and this is an accepted and important indication for the technology.
Self-reported ACE inhibitor use was associated with a higher odds of normal ABPM compared with those not on an ACE inhibitors. Because a significant portion of those with controlled ambulatory BP were also on therapy, this suggests that perhaps those who are not on ACE inhibitors may benefit from this therapy in terms of better BP management, but we are unable to infer causality in this analysis. The relationship is complex, and this finding may also be explained by the Model was adjusted for age, sex, and CKD diagnosis (glomerular vs nonglomerular underlying cause of CKD). CKD indicates chronic kidney disease; GFR, glomerular filtration rate; ABPM, ambulatory blood pressure monitoring; uPrCr, urine protein:creatinine ratio.
extensive use of ACE inhibitors for their antiproteinuric effect in subjects without a history of HTN. Furthermore, there may be significant confounding in this relationship (ie, those who have good BP control may be taking ACE inhibitors for CKD management unrelated to their BP status), and this is important to note in interpreting the association.
The present analysis also describes the association between renal function decline and the presence of abnormal ABPM. A more dramatic 1-year decline in function (ie, a decrease in GFR as well as an increase in uPrCr) was associated with higher odds of abnormal ABPM. Interestingly, a 1-SD increase in uPrCr level ratio (ie, level at visit 2/level at visit 1) was more strongly associated with odds of an abnormal ABPM than a 1-SD decrease in GFR level ratio (OR, 1.39 versus 1.26). In this model, which adjusted for important covariates, the effect for uPrCr level ratio was significant (Pϭ0.019), whereas the effect for GFR level ratio was borderline significant (Pϭ0.081) with the same trend. Also of note, the average levels of GFR and uPrCr were not significantly associated with having an abnormal ABPM, in contrast to the change in levels.
Perspectives
In conclusion, ABPM has emerged as an important diagnostic tool to aid clinicians in detecting increased cardiovascular risk in patients with CKD. This analysis demonstrates the feasibility of measuring ABPM in a multicenter trial, highlights the significant burden of HTN in patients with CKD, and reveals an important association between CKD progression and the presence of ambulatory HTN. Given these important findings, ABPM should be used to monitor risk and trigger therapeutic interventions in children with CKD.
